JP2005518405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518405A5 JP2005518405A5 JP2003559491A JP2003559491A JP2005518405A5 JP 2005518405 A5 JP2005518405 A5 JP 2005518405A5 JP 2003559491 A JP2003559491 A JP 2003559491A JP 2003559491 A JP2003559491 A JP 2003559491A JP 2005518405 A5 JP2005518405 A5 JP 2005518405A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- composition according
- polyol
- composition
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 51
- 238000009472 formulation Methods 0.000 claims 22
- 229920005862 polyol Polymers 0.000 claims 15
- 150000003077 polyols Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 4
- 229940112822 Chewing Gum Drugs 0.000 claims 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 3
- 235000015218 chewing gum Nutrition 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000005056 compaction Methods 0.000 claims 2
- 229920000591 gum Polymers 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- YCKSFFKKEWTLIZ-UHFFFAOYSA-N 2-(4-benzhydrylpiperazin-1-ium-1-yl)acetate Chemical compound C1CN(CC(=O)O)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 YCKSFFKKEWTLIZ-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-ium-1-yl]ethoxy]acetate Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-N Acesulfame potassium Chemical compound [K+].CC1=CC(=O)NS(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-N 0.000 claims 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 1
- 229960003438 Aspartame Drugs 0.000 claims 1
- 108010011485 Aspartame Proteins 0.000 claims 1
- 229940109275 Cyclamate Drugs 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229940081974 Saccharin Drugs 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940085605 Saccharin Sodium Drugs 0.000 claims 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 claims 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- 230000003113 alkalizing Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000605 aspartame Substances 0.000 claims 1
- 235000010357 aspartame Nutrition 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 150000004676 glycans Polymers 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N levocetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 229960003308 levocetirizine dihydrochloride Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
Claims (22)
- 少なくとも2つの別の処方を含む経口医薬組成物であって:
一般式Iを有する2−[4−(ジフェニルメチル)−1−ピペラジニル]−酢酸及びそれらのアミドから選ばれた活性化合物を含む第一の処方
式中、
R1は−COOH基又は−CONH2基であり、
X1及びX2は、独立して、それぞれ水素原子、ハロゲン原子、直鎖又は分枝C1−C4アルコキシ基又はトリフルオロメチル基並びにそれらの医薬品的に許容できる塩、幾何学的異性体、鏡像異性体、ジアステレオマ及びそれらの混合物であり、その第一の処方が、ポリオールと式Iの活性化合物の10を超すモル比で、300未満の分子量のポリオールを含まない;及び
分子量が3000未満の1つ又はそれ以上の固体ポリオールを含み、如何なる薬物も含まない第二の処方、
を含む経口医薬組成物。 - 第一の処方が、ラクトースは例外として、ポリオールをポリオールと式Iの活性化合物の10を超すモル比で、分子量950未満のポリオールを含まない請求項1記載の組成物。
- 第一の処方が、ポリオールと式Iの活性化合物の5を超すモル比で、分子量300未満のポリオールを含まない請求項1記載の組成物。
- 第一の処方が、分子量300未満のポリオールを含まない請求項1〜3のいずれか一項に記載の組成物。
- 第一の処方が、ラクトースは例外として、ポリオールと式Iの活性化合物の5を超すモル比で、分子量950未満のポリオールを含まない請求項1〜3のいずれか一項に記載の組成物。
- 第一の処方が、ラクトースは例外として、分子量950未満のポリオールを含まない請求項1〜5のいずれか一項に記載の組成物。
- 処方が粉末、顆粒、溶液又は懸濁液の形で調製される請求項1〜6のいずれか一項に記載の組成物。
- 第二の処方中のポリオールがマンニトールである請求項1〜7のいずれか一項に記載の組成物。
- 第二の処方中のポリオールが多糖類である請求項1〜7のいずれか一項に記載の組成物。
- 少なくとも1つの処方が、更にアルカリ化剤を含む請求項1〜9のいずれか一項に記載の組成物。
- アルカリ化剤がクエン酸ナトリウムである請求項10記載の組成物。
- 第一の処方が、サイクロデキストリン、コロイド状無水シリカ、微結晶セルロース、ステアリン酸マグネシウム、フレーバー又は着色剤から選ばれた1つ又はそれ以上の賦形剤を更に含む請求項1〜10のいずれか一項に記載の組成物。
- 第一の処方が、アセサルフエームK、アスパルテーム、サッカリン、サッカリンナトリウム又はシクラメートのような非ポリオール甘味剤を更に含む請求項1〜12のいずれか一項に記載の組成物。
- 第一の処方の活性化合物がセチリジンジハイドロクロライド、レボセチリジンジハイドロクロライド又はエフレトリジンジハイドロクロライドである請求項1〜13のいずれか一項に記載の組成物。
- チューインガム、錠剤又は沸騰錠剤の形である請求項1〜14のいずれか一項に記載の組成物。
- 各層が処方の1つから調製される多層錠剤の形である請求項15記載の組成物。
- 不活性層が2つの処方から調製された層を隔てる多層錠剤の形である請求項16記載の組成物。
- 処方の1つから調製された内部コアを有し、他の処方から調製される外部殻を有する錠剤である請求項15記載の組成物。
- 第一の処方から作られ、更にガム基材を含むコア、及び
第二の処方から作られたコーティング、
を含むチューインガムである請求項15記載の組成物。 - 第二の処方から作られ、更にガム基材を含むコア、及び
第一の処方から作られたコーティング、
を含むチューインガムである請求項15記載の組成物。 - 1つの型の顆粒が、第一の処方の閉め固めで作られ、他の型の顆粒が、第二の処方の閉め固めで作られる、2つの型の顆粒の混合物から調製された乾燥シロップである請求項1〜14のいずれか一項に記載の組成物。
- 請求項1〜21のいずれか一項に記載の組成物を製造する方法であって、第一の処方と第二の処方を別々に調製し、2つの処方を組み合わせることによる製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02000871 | 2002-01-15 | ||
EP02000871.0 | 2002-01-15 | ||
PCT/EP2003/000260 WO2003059328A1 (en) | 2002-01-15 | 2003-01-14 | Formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010035633A Division JP5467685B2 (ja) | 2002-01-15 | 2010-02-22 | 処方 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005518405A JP2005518405A (ja) | 2005-06-23 |
JP2005518405A5 true JP2005518405A5 (ja) | 2006-01-05 |
JP4724367B2 JP4724367B2 (ja) | 2011-07-13 |
Family
ID=8185261
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003559491A Expired - Lifetime JP4724367B2 (ja) | 2002-01-15 | 2003-01-14 | 処方 |
JP2010035633A Expired - Lifetime JP5467685B2 (ja) | 2002-01-15 | 2010-02-22 | 処方 |
JP2012051259A Expired - Lifetime JP5623447B2 (ja) | 2002-01-15 | 2012-03-08 | 処方 |
JP2013228128A Abandoned JP2014024866A (ja) | 2002-01-15 | 2013-11-01 | 処方 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010035633A Expired - Lifetime JP5467685B2 (ja) | 2002-01-15 | 2010-02-22 | 処方 |
JP2012051259A Expired - Lifetime JP5623447B2 (ja) | 2002-01-15 | 2012-03-08 | 処方 |
JP2013228128A Abandoned JP2014024866A (ja) | 2002-01-15 | 2013-11-01 | 処方 |
Country Status (20)
Country | Link |
---|---|
US (3) | US20050038039A1 (ja) |
EP (1) | EP1467715B1 (ja) |
JP (4) | JP4724367B2 (ja) |
KR (1) | KR101005648B1 (ja) |
CN (2) | CN100455287C (ja) |
AT (1) | ATE486587T1 (ja) |
AU (3) | AU2003201161B2 (ja) |
BR (1) | BR0306870A (ja) |
CA (1) | CA2472396A1 (ja) |
CO (1) | CO5590918A2 (ja) |
DE (1) | DE60334773D1 (ja) |
ES (1) | ES2354688T3 (ja) |
HK (1) | HK1076605A1 (ja) |
MX (1) | MXPA04006775A (ja) |
NO (1) | NO333936B1 (ja) |
NZ (1) | NZ534039A (ja) |
PL (1) | PL212123B1 (ja) |
RU (1) | RU2004123612A (ja) |
WO (1) | WO2003059328A1 (ja) |
ZA (1) | ZA200404796B (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0308927A (pt) * | 2002-04-04 | 2005-01-04 | Pfizer Prod Inc | Comprimido mastigável de sabor agradável |
JP5091661B2 (ja) * | 2004-04-01 | 2012-12-05 | ピエール ファーブル メディカモン | 超臨界co2と錯体相互作用剤を用いる方法によって得られる包接錯体 |
US7780985B2 (en) * | 2005-07-12 | 2010-08-24 | Accu-Break Technologies, Inc. | Tablets having a printed separation mark to guide breaking |
US7622137B2 (en) * | 2004-05-21 | 2009-11-24 | Accu-Break Technologies, Inc. | Dosage forms contained within a capsule or sachet |
US7329418B2 (en) * | 2004-05-21 | 2008-02-12 | Accu Break Technologies, Inc. | Pharmaceutical tablets having height greater than width |
US7838031B2 (en) | 2004-05-21 | 2010-11-23 | Lawrence Solomon | Method of administering a partial dose using a segmented pharmaceutical tablet |
US7318935B2 (en) * | 2004-05-21 | 2008-01-15 | Accu-Break Technologies, Inc. | Pharmaceutical tablets with active and inactive segments |
US7713547B2 (en) | 2004-05-21 | 2010-05-11 | Accu-Break Pharmaceuticals, Inc. | Method of administering a partial dose of a segmented pharmaceutical tablet |
CA2564960A1 (en) * | 2004-05-21 | 2005-12-01 | Lawrence Solomon | Pharmaceutical tablets having a separation mark positioned on the side of said tablets |
US20080075784A1 (en) * | 2004-07-22 | 2008-03-27 | Pfizer Inc. | Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form |
US20060083786A1 (en) * | 2004-07-29 | 2006-04-20 | Glenmark Pharmaceuticals Limited | Taste masking pharmaceutical composition containing levocetirizine |
KR100714616B1 (ko) * | 2005-06-23 | 2007-05-07 | 삼성전기주식회사 | 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기 |
US20070086974A1 (en) * | 2005-10-06 | 2007-04-19 | Gawande Rahul S | Cetirizine compositions |
BRPI0520797B8 (pt) * | 2005-11-18 | 2021-05-25 | Accu Break Tech Inc | forma de dosagem farmacêutica comprimida em bicamadas |
US20070237815A1 (en) * | 2006-04-06 | 2007-10-11 | Lawrence Solomon | Dosage forms and methods comprising amlodipine and chlorthalidone |
US20090269393A1 (en) * | 2006-06-12 | 2009-10-29 | Jubliant Organosys Limited | Chewable Bilayer Tablet Formulation |
JP2010500374A (ja) * | 2006-08-08 | 2010-01-07 | エーシーシーユー−ブレイク テクノロジーズ,インク. | 複数の活性セグメントを含む薬剤の錠剤 |
WO2008067485A1 (en) * | 2006-11-30 | 2008-06-05 | Accu-Break Technologies, Inc. | Divisible osmotic dosage forms and methods of use |
US20090004231A1 (en) | 2007-06-30 | 2009-01-01 | Popp Shane M | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring |
WO2009006898A1 (en) * | 2007-07-11 | 2009-01-15 | Fertin Pharma A/S | Stable medicated chewing gum comprising cyclodextrin inclusion complex |
EP2550967A1 (en) * | 2007-07-11 | 2013-01-30 | Fertin Pharma A/S | Compressed chewing gum tablet comprising taste-masking agent |
CN102046021A (zh) * | 2008-05-26 | 2011-05-04 | 费尔廷制药公司 | 膜包衣压缩口香糖 |
AU2009288006B2 (en) * | 2008-09-05 | 2014-07-17 | Mcneil-Ppc, Inc. | Method for making cetirizine tablets |
WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
WO2011110939A2 (en) | 2010-03-11 | 2011-09-15 | Rubicon Research Private Limited | Pharmaceutical compositions of substituted benzhydrylpiperazines |
EP2571484A2 (en) * | 2010-05-18 | 2013-03-27 | Mahmut Bilgic | Effervescent formulations |
JP6506301B2 (ja) * | 2014-03-27 | 2019-04-24 | ユセベ ファルシム ソシエテ アノニム | レボセチリジンを含む医薬組成物 |
JP2016094364A (ja) * | 2014-11-14 | 2016-05-26 | ニプロ株式会社 | 安定化および苦味抑制された口腔内崩壊製剤 |
JP7049610B2 (ja) * | 2018-05-21 | 2022-04-07 | 高田製薬株式会社 | レボセチリジン固形製剤 |
JP2023517346A (ja) | 2020-02-03 | 2023-04-25 | ジョンソン アンド ジョンソン コンシューマー インコーポレイテッド | セチリジンを含む単層チュアブル錠剤 |
US20230366038A1 (en) * | 2022-05-16 | 2023-11-16 | Bioo Scientific Corporation | Compositions and methods relating to loop mediated isothermal amplification (lamp) |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4238510A (en) * | 1979-02-21 | 1980-12-09 | Life Savers, Inc. | Sugarless coating for chewing gum and confections and method |
US4260596A (en) * | 1979-08-13 | 1981-04-07 | Bristol-Myers Company | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same |
FR2647343B1 (fr) | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
US5460825A (en) * | 1990-05-23 | 1995-10-24 | Mcneil-Ppc, Inc. | Taste mask coatings for preparing chewable pharmaceutical tablets |
NZ243667A (en) * | 1991-08-02 | 1995-02-24 | Kurihara Yoshie | Chewing gum containing coated curculin derivative or fruit containing curculin |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
US5380530A (en) * | 1992-12-29 | 1995-01-10 | Whitehill Oral Technologies | Oral care composition coated gum |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
IT1274034B (it) * | 1994-07-26 | 1997-07-14 | Applied Pharma Res | Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione |
US5866179A (en) * | 1996-05-03 | 1999-02-02 | Avant-Garde Technologies & Products S.A. | Medicated chewing gum and a process for preparation thereof |
EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
US6172095B1 (en) * | 1996-11-25 | 2001-01-09 | The Procter & Gamble Company | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
BE1011251A3 (fr) * | 1997-07-03 | 1999-06-01 | Ucb Sa | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine. |
ES2236768T3 (es) * | 1997-07-10 | 2005-07-16 | DR. GERGELY & CO. | Comprimido masticable, en grageas, soluble, que contiene goma. |
DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
US6627234B1 (en) * | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
WO2002013781A1 (en) | 2000-08-14 | 2002-02-21 | Fertin Pharma A/S | Method for preparation of chewing gum with customer acceptable taste |
WO2002049607A2 (en) * | 2000-12-20 | 2002-06-27 | Firmenich Sa | Flavoured oral drug delivery system |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
US7014867B2 (en) * | 2001-06-28 | 2006-03-21 | Ucb Farchim Sa | Tablet comprising cetirizine and pseudoephedrine |
BR0308927A (pt) * | 2002-04-04 | 2005-01-04 | Pfizer Prod Inc | Comprimido mastigável de sabor agradável |
-
2003
- 2003-01-14 EP EP03729449A patent/EP1467715B1/en not_active Expired - Lifetime
- 2003-01-14 ES ES03729449T patent/ES2354688T3/es not_active Expired - Lifetime
- 2003-01-14 BR BR0306870-6A patent/BR0306870A/pt not_active Application Discontinuation
- 2003-01-14 NZ NZ534039A patent/NZ534039A/en not_active IP Right Cessation
- 2003-01-14 WO PCT/EP2003/000260 patent/WO2003059328A1/en active Application Filing
- 2003-01-14 DE DE60334773T patent/DE60334773D1/de not_active Expired - Lifetime
- 2003-01-14 AT AT03729449T patent/ATE486587T1/de not_active IP Right Cessation
- 2003-01-14 RU RU2004123612/15A patent/RU2004123612A/ru unknown
- 2003-01-14 PL PL370292A patent/PL212123B1/pl unknown
- 2003-01-14 MX MXPA04006775A patent/MXPA04006775A/es active IP Right Grant
- 2003-01-14 CN CNB038022869A patent/CN100455287C/zh not_active Expired - Lifetime
- 2003-01-14 AU AU2003201161A patent/AU2003201161B2/en not_active Ceased
- 2003-01-14 KR KR1020047010865A patent/KR101005648B1/ko active IP Right Grant
- 2003-01-14 CN CN200910005882XA patent/CN101632642B/zh not_active Expired - Lifetime
- 2003-01-14 US US10/501,359 patent/US20050038039A1/en not_active Abandoned
- 2003-01-14 JP JP2003559491A patent/JP4724367B2/ja not_active Expired - Lifetime
- 2003-01-14 CA CA002472396A patent/CA2472396A1/en not_active Abandoned
-
2004
- 2004-06-17 ZA ZA200404796A patent/ZA200404796B/en unknown
- 2004-07-14 CO CO04067032A patent/CO5590918A2/es not_active Application Discontinuation
- 2004-08-13 NO NO20043367A patent/NO333936B1/no not_active IP Right Cessation
-
2005
- 2005-09-29 HK HK05108624.2A patent/HK1076605A1/xx not_active IP Right Cessation
-
2008
- 2008-05-23 AU AU2008202280A patent/AU2008202280B2/en not_active Ceased
- 2008-08-28 US US12/230,420 patent/US8946229B2/en active Active
-
2009
- 2009-07-27 AU AU2009203044A patent/AU2009203044B2/en not_active Ceased
-
2010
- 2010-02-22 JP JP2010035633A patent/JP5467685B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-23 US US13/242,378 patent/US20120010218A1/en not_active Abandoned
-
2012
- 2012-03-08 JP JP2012051259A patent/JP5623447B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-01 JP JP2013228128A patent/JP2014024866A/ja not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005518405A5 (ja) | ||
JP5623447B2 (ja) | 処方 | |
JP2010120963A6 (ja) | 処方 | |
JP2005533860A5 (ja) | ||
JP2008511569A (ja) | 注意欠如活動過多障害の治療方法 | |
JP2009506014A5 (ja) | ||
JP2002511102A (ja) | ピペリジノアルカノール−鬱血除去剤の組合せ用医薬組成物 | |
JP2007091758A5 (ja) | ||
JP5628910B2 (ja) | 6−(5−クロロ−2−ピリジル)−5−[(4−メチル−1−ピペラジニル)カルボニルオキシ]−7−オキソ−6,7−ジヒドロ−5h−ピロロ[3,4−b]ピラジンの配合物 | |
JP3182423B2 (ja) | シサプリドの経口用徐放性組成物 | |
US20080206331A1 (en) | Tablet comprising efletirizine and pseudoephedrine | |
JP2000178204A (ja) | ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤 | |
JP2004509870A5 (ja) | ||
US20070299054A1 (en) | Oral pharmaceutical composition of a poorly water-soluble active agent | |
WO2013081567A1 (en) | Effervescent antipsychotic formulations | |
JP2009541267A (ja) | 低い水溶性活性物質の経口製薬学的組成物 |